Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.18 USD
Change Today +0.09 / 0.89%
Volume 134.3K
FOMX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

foamix pharmaceuticals ltd (FOMX) Snapshot

Open
$10.02
Previous Close
$10.09
Day High
$10.30
Day Low
$9.85
52 Week High
05/27/15 - $14.00
52 Week Low
10/10/14 - $4.75
Market Cap
306.3M
Average Volume 10 Days
248.3K
EPS TTM
--
Shares Outstanding
30.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FOAMIX PHARMACEUTICALS LTD (FOMX)

Related News

No related news articles were found.

foamix pharmaceuticals ltd (FOMX) Related Businessweek News

No Related Businessweek News Found

foamix pharmaceuticals ltd (FOMX) Details

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for the treatment of acne, impetigo, and other skin conditions in the United States, Germany, and Israel. Its lead product candidates include FMX101, a novel topical foam formulation which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. The company is also developing FMX103, a version of FMX101 to treat rosacea; and FDX104 to treat chemotherapy-induced rashes, as well as early-stage stable foam formulations of various drugs for the treatment of dermatological indications, including atopic dermatitis, psoriasis, genital warts and actinic keratoses, and herpes and fungal infections. It has development and license agreements with Bayer HealthCare AG, Merz Pharmaceuticals, LLC, and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

29 Employees
Last Reported Date: 03/17/15
Founded in 2003

foamix pharmaceuticals ltd (FOMX) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $320.3K
President and President of Foamix Pharmaceuti...
Total Annual Compensation: $230.0K
Co-Founder, Chairman of the Board and Chief I...
Total Annual Compensation: $320.1K
Chief Financial Officer
Total Annual Compensation: $141.7K
Executive Vice President of Intellectual Prop...
Total Annual Compensation: $185.8K
Compensation as of Fiscal Year 2014.

foamix pharmaceuticals ltd (FOMX) Key Developments

Foamix Pharmaceuticals Ltd. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015

Foamix Pharmaceuticals Ltd. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $109,000 against $598,000 a year ago, the reduction was due to completion of certain development projects for licensees that generated development fees during 2014, and which resulting products are now in clinical trial phases or pending commercialization and therefore are not generating development fees at this time. Operating loss was $4,722,000 against $301,000 a year ago. Loss for the period was $4,647,000 or $0.18 per basic and diluted share against $3,432,000 or $0.30 per basic and diluted share a year ago. For the six months, the company reported revenues of $557,000 against $2,006,000 a year ago. Operating loss was $7,789,000 against income of $144,000 a year ago. Loss for the period was $7,732,000 or $0.30 per basic and diluted share against $3,473,000 or $0.30 per basic and diluted share a year ago. The increase in net loss is due to non-cash finance expenses. Net cash used in operating activities was $5,782,000 against net cash provided by operating activities of $570,000 a year ago. Purchase of fixed assets was $149,000 against $89,000 a year ago.

Foamix Pharmaceuticals Ltd. to Report Q2, 2015 Results on Aug 20, 2015

Foamix Pharmaceuticals Ltd. announced that they will report Q2, 2015 results at 1:00 PM, GMT Standard Time on Aug 20, 2015

Foamix Pharmaceuticals Ltd., Q2 2015 Earnings Call, Aug 20, 2015

Foamix Pharmaceuticals Ltd., Q2 2015 Earnings Call, Aug 20, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOMX:US $10.18 USD +0.09

FOMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Heron Therapeutics Inc $35.46 USD +0.10
Johnson & Johnson $95.17 USD -1.05
Sanofi €88.44 EUR -0.12
View Industry Companies
 

Industry Analysis

FOMX

Industry Average

Valuation FOMX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 66.5x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 60.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FOAMIX PHARMACEUTICALS LTD, please visit www.foamix.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.